Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Natriuretic Effect of GLP-1 in Healthy Subjects
NCT02130778Phase 1Completed
- Sponsor
- Clinical Hospital Center Zagreb
- Start
- Apr 2014
- Primary completion
- Oct 2015
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Glucagon-like peptide 1 in hypertension (HTN) (2 arms), sponsored by Clinical Hospital Center Zagreb. Primary endpoint: Evidence of the positive effect on natriuresis (level of sodium in urine sample). Started Apr 2014; status: completed.
02
Drugs
Glucagon-like peptide 1
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT02130778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02130778.